Abstract: Clostridium difficile infection has been shown to cause a defective intestinal epithelial tight junction barrier. IL-1β, IL-6, and TNF-α are hypothesized to be the main players in the development of intestinal inflammation and cause an increase in intestinal tight junction permeability. This study showed that cytokines had different effects on tight junction disruption based on either low or high concentration. Both C. difficile toxins were able to disrupt tight junctions, although TcdB had a greater effect overall. We also tested the toxins' ability to induce NF-kB activation, and based on the results, TcdB was more potent than TcdA in inducing NF-kB.Summary: C. difficile infection has been shown to cause a defective intestinal epithelial tight junction barrier. IL-1β, IL-6, and TNF-α are hypothesized to be the main players in the development of intestinal inflammation and cause an increase in tight junction permeability. This study aims to show the effects of those cytokines and toxins on tight junction barrier over time.
Ask the author a question about this poster.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
VITVO: Mimicking In Vivo Complexity By The Innovative 3D Model
Olivia Candini1, Giulia Grisendi1, Elisabetta Manuela Foppiani1, Matteo Brogli1, Beatrice Aramini2, Valentina Masciale3, Carlotta Spano1, Tiziana Petrachi4, Elena Veronesi4, Pierfranco Conte5,6, Giorgio Mari1 & Massimo Dominici1,3
Cancer Vaccine, Your T-cell guru: A Bioengineering Approach for Cancer Therapy
Zaween Hanis Bt Mohamad Shamsul, Sam Pei Fong, Chin Chin Liew, Chia Jin Chuah, Turgaa Shini Devaraj, Nur’Awatif Ishak, Sheng Keat Siah, Muhammad Nur Syazwan Md Zin, Kar Cheng Wong
What are HIV and AIDS
Karwan M. Qadr and Abdulla Azad
Multiplex miRNA Profiling for Biomarker Discovery and Verification Studies Using the FirePlex® Platform
M. Tackett, B. Heinrich, I. Diwan, G. Tejada, C. Rafferty, E. Atabakhsh, and D. Pregibon
Accelerating high-throughput screening with FirePlex®-HT:An automatable, multiplex immunoassay using FirePlex® Particle Technology
A. Perea, B. Heinrich, W. Austin, C. Rafferty, M. Camilleri, L. To, E. Atabakhsh, and D. Pregibon